ReviewPneumonia (Nathan Qld.)2016
Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.
Review in Pneumonia (Nathan Qld.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Clinical differentiation between pediatric pulmonary tuberculosis andExperimental and therapeutic medicine · 2026Review
- Coexisting Lung Cancer and Pulmonary Tuberculosis: A Comprehensive Review From Incidence to Management.Cancer reports (Hoboken, N.J.) · 2025Review
- Bode Phase Angle Signaling of a TB Disease Biomarker.Molecules (Basel, Switzerland) · 2023Article
- Genetic diversity and drug sensitivity profile of Mycobacterium tuberculosis among children in Ethiopia.PloS one · 2023Article
- Opportunities for Mobile App-Based Adherence Support for Children With Tuberculosis in South Africa.JMIR mHealth and uHealth · 2020Article
- Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling.The Lancet. Infectious diseases · 2019Article
- Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.IUBMB life · 2018Review
- Pediatric multi-drug resistant-tuberculosis and HIV co-infection in a resource-limited setting: a case report.BMC research notes · 2018Article
- Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis.Indian journal of microbiology · 2017Review
- Childhood tuberculosis-out of the shadows.Pneumonia (Nathan Qld.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last 10 years, interest in pediatric tuberculosis (TB) has increased dramatically, together with increased funding and research. We have a better understanding of the burden of childhood TB as well as a better idea of how to diagnose it. Our appreciation of pathophysiology is improved and with it investigators are beginning to consider pediatric TB as a heterogeneous entity, with different types and severity of disease being treated in different ways. There have been advances in how to treat both TB infection and TB disease caused by both drug-susceptible as well as drug-resistant organisms. Two completely novel drugs, bedaquiline and delamanid, have been developed, in addition to the use of older drugs that have been re-purposed. New regimens are being evaluated that have the potential to shorten treatment. Many of these drugs and regimens have first been investigated in adults with children an afterthought, but increasingly children are being considered at the outset and, in some instances studies are only conducted in children where pediatric-specific issues exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.